Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Enrolling By Invitation NCT05607810

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Conditions: Diabetic Macular Edema, Diabetic Retinopathy

Sex: All

Ages: 18 Years – N/A

Enrollment: 22

Sponsor: Adverum Biotechnologies, Inc.

Location: United States

Summary

This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME). Participants who previously participated in the INFINITY parent study and received a single unilateral intravitreal dose of ADVM-022 are eligible for enrollment upon completion of the end of study visit in the parent study.

Eligibility Criteria

Inclusion Criteria:Must have participated in the ADVM-022-04 [INFINITY] (parent) study and received ADVM-022Must provide signed informed consentMust be willing and able to comply with all study proceduresExclusion Criteria:- None

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05607810). StuddyBuddy aggregates publicly available trial information.